This site uses cookies. By using this site you agree to receiving cookies. View Policy.

245%
Raised
£737,480
Investors
653
Target
£300,000
Equity
11.76%
Pre-money valuation
£5,534,124

Molecular Warehouse, backed by Oxford Technology, has a disruptive, patent-pending biosensor technology designed to enable people to monitor their health using their smartphones. First applications will be for kidney transplantation and chronic stress. The in vitro diagnostic device market is $58bn.

  • Obtained £1.2m in funding since incorporation in March 2015
  • Comprehensive IP strategy with 5 international patents filed
  • Hardware prototype and MVP for App and Web dashboard developed
  • Experienced team and backing from specialised VCs

Idea

Each year, millions of people die because they didn’t know they had a health problem, or because they learnt about it too late.

Our vision is to create a world where most diseases are prevented, by giving people the ability to monitor and manage their health using their smartphones, anywhere, anytime.

To achieve this, we are working to re-engineer the most successful personal diagnostic system, the glucose monitor, which millions of diabetic patients use every day, to be able to detect many other diseases.

For our first tests we focus on helping kidney disease patients. Almost 10% of the population worldwide suffer chronic kidney disease, and there are 2m patients in dialysis and 1m patients with a kidney transplant.

Poor monitoring and drug adherence cause 36% of kidney graft losses, and 20% of dialysis patients die while they wait for a new kidney. With our system, patients will be able to monitor themselves at home, and communicate the results with their doctor.

We are expanding to multiple other applications, such as chronic stress and heart disease, so we can help not just millions, but hundreds of millions of people worldwide.

KEY ACHIEVEMENTS

- Raised over £635K in equity funding since incorporation in March 2015

- Secured £570K in grants for development of our first tests

- Comprehensive IP strategy with 5 international patents filed

- Developed hardware prototype and MVP for App and Web dashboard

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the Molecular Warehouse pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

Molecular Warehouse has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.